Cargando…

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern

SARS-CoV-2 variants of concern (VOCs) have shown resistance to vaccines targeting the original virus strain. An mRNA vaccine encoding the spike protein of Omicron BA1 (BA1-S-mRNA) was designed, and its neutralizing activity, with or without the original receptor-binding domain (RBD)-mRNA, was tested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Gang, Shi, Juan, Verma, Abhishek K., Guan, Xiaoqing, Perlman, Stanley, Du, Lanying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711903/ https://www.ncbi.nlm.nih.gov/pubmed/36471872 http://dx.doi.org/10.1016/j.isci.2022.105690

Ejemplares similares

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern
por: Shi, Juan, et al.
Publicado: (2022)

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
por: Guan, Xiaoqing, et al.
Publicado: (2023)

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022)

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
por: Ju, Bin, et al.
Publicado: (2023)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
por: Chen, Chuan, et al.
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
por: Zhu, Ka-Li, et al.
Publicado: (2023)

A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants
por: Wang, Rui, et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)

BF.7 Omicron subvariant in India and China: a raising concern – correspondence
por: Sah, Ranjit, et al.
Publicado: (2023)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Comparison of the replication and neutralization of different SARS‐CoV‐2 Omicron subvariants in vitro
por: Zhang, Yaqing, et al.
Publicado: (2023)

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
por: Faraone, Julia N., et al.
Publicado: (2023)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
por: Chiang, Hsiao-Ling, et al.
Publicado: (2023)

Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients
por: Deng, Haohui, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
por: Yang, Jingyun, et al.
Publicado: (2023)

Genomic evidence for reinfection with different Omicron subvariants
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
por: Lyngse, Frederik Plesner, et al.
Publicado: (2022)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients
por: Chen, Jun, et al.
Publicado: (2023)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
por: Moriyama, Saya, et al.
Publicado: (2023)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C. Paul, et al.
Publicado: (2022)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2m1ubga1hpcne1bn8c647gkq4d